Protagonist Therapeutics Inc [NASDAQ: PTGX] traded at a low on Tuesday, posting a -1.73 loss after which it closed the day’ session at $34.59.
The results of the trading session contributed to over 12520105 shares changing hands. Over the past one week, the price volatility of Protagonist Therapeutics Inc stands at 4.29% while the volatility over the past one month is 5.39%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for PTGX stock reached $2.03 billion, with 57.71 million shares outstanding and 55.40 million shares in the current float. Compared to the average trading volume of 675.68K shares, PTGX reached a trading volume of 12520105 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Protagonist Therapeutics Inc [PTGX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PTGX shares is $43.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PTGX stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
CapitalOne have made an estimate for Protagonist Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 30, 2023. While these analysts kept the previous recommendation, Jefferies raised their target price from $30 to $40. The new note on the price target was released on May 25, 2023, representing the official price target for Protagonist Therapeutics Inc stock. Previously, the target price had yet another raise to $21, while JMP Securities analysts kept a Mkt Outperform rating on PTGX stock.
The Average True Range (ATR) for Protagonist Therapeutics Inc is set at 1.63, with the Price to Sales ratio for PTGX stock in the period of the last 12 months amounting to 6.44. The Price to Book ratio for the last quarter was 3.62, with the Price to Cash per share for the same quarter was set at 5.50.
How has PTGX stock performed recently?
Protagonist Therapeutics Inc [PTGX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.08. With this latest performance, PTGX shares gained by 22.88% in over the last four-week period, additionally plugging by 50.85% over the last 6 months – not to mention a rise of 25.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PTGX stock in for the last two-week period is set at 61.87, with the RSI for the last a single of trading hit 63.98, and the three-weeks RSI is set at 60.64 for Protagonist Therapeutics Inc [PTGX]. The present Moving Average for the last 50 days of trading for this stock 30.12, while it was recorded at 33.62 for the last single week of trading, and 24.34 for the last 200 days.
Protagonist Therapeutics Inc [PTGX]: Deeper insight into the fundamentals
Protagonist Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.72 and a Current Ratio set at 15.72.
Insider trade positions for Protagonist Therapeutics Inc [PTGX]
The top three institutional holders of PTGX stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in PTGX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in PTGX stock with ownership which is approximately 5.1238%.
